First use of Creatine Hydrochloride in Premanifest Huntington Disease
Huntington disease is a devastating autosomal dominant neurodegenerative disorder that typically manifests between ages 30 and 50 years. Promising high-dose creatine monophosphate trials have been limited by patient tolerance.
This is the first report of use of creatine hydrochloride in two premanifest Huntington disease patients, with excellent tolerability over more than 2 years of use.
Medical Journal of Australia
Reading: journal; textbook; book; literature review
0h : 30m
MBA: 0h : 30m
Medical Practitioner, Medical Student, Doctor-in-Training, Non-Vocationally Registered, Pharmacist, Researcher, Retired, Specialist - Other, Specialist General Practitioner